30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
Journal for ImmunoTherapy of Cancer volume 3, Article number: P327 (2015)
The human Vγ9Vδ2 T cells are a unique T cell type, and recent studies of the biology of Vγ9Vδ2 T cells emphasize the potential exploitation of these cells in immunotherapy of cancer. Vγ9Vδ2 T cells exhibit dual functionality in that they are both antigen presenting cells (APC) and cytotoxic towards cancer cells. We show that Vγ9Vδ2 T cells can kill cancer cell lines from various cancer types such as leukemia, melanoma, prostate-, and breast cancer, with a significantly increased killing upon treatment of the cancer cells with Zoledronic acid. In addition, we show that Vγ9Vδ2 T cells take up tumor antigens gp100 and MART-1 (long peptide and recombinant protein, respectively), and process these antigens for presentation of class I restricted peptides in the context of the HLA-A02.01 molecule, to be recognized by peptide specific cytotoxic CD8 T cells. Moreover, we show that specific inhibition of the proteasome by lactacystin impair recognition by peptide specific CD8 T cells, strongly suggesting proteasome involvement in presentation of the relevant class I restricted peptides. The dual functions; killing and antigen presentation combined with the ease of expanding Vγ9Vδ2 T cells in vitro from peripheral blood lymphocytes to billions of cells, makes Vγ9Vδ2 T cells attractive vehicles for adoptive cell therapy (ACT) in cancer therapy. Thus, Vγ9Vδ2 T cells are broadly tumor specific killers, that concurrently could induce or support tumor specific αβ-T cell responses.
About this article
Cite this article
Olofsson, G.H., Idorn, M., Schenker, R. et al. Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells. j. immunotherapy cancer 3 (Suppl 2), P327 (2015). https://doi.org/10.1186/2051-1426-3-S2-P327